Rationally designed peptoids modulate aggregation of amyloid-beta 40

Area of Science:

• Neuroscience
• Biochemistry
• Drug Discovery

Background:

• Alzheimer's disease (AD) is a leading cause of death, characterized by amyloid-beta (Aβ) plaque accumulation in the brain.
• Current therapeutic strategies to prevent Aβ aggregation have not yet yielded a definitive treatment.
• Aβ plaques are associated with neurodegeneration and cognitive decline.

Purpose of the Study:

• To investigate the potential of a peptoid-based molecule, JPT1, as a therapeutic agent to modulate Aβ aggregation.
• To evaluate JPT1's ability to inhibit the formation of disease-associated β-sheet amyloid aggregates.

Main Methods:

• A peptoid molecule, JPT1, designed as a mimic of the Aβ peptide fragment KLVFF, was synthesized.
• JPT1 incorporates chiral, aromatic side chains to promote a stable helical secondary structure for enhanced interaction with Aβ.
• Aβ40 aggregation kinetics and aggregate structure were analyzed in the presence of JPT1.

Main Results:

• JPT1 was found to modulate the aggregation of amyloid-beta 40 (Aβ40).
• Specifically, JPT1 decreased the lag phase before β-sheet aggregate formation and reduced the total number of fibrillar, β-sheet aggregates.
• These findings indicate JPT1 influences the kinetics and extent of Aβ aggregation.

Conclusions:

• Peptoid-based molecules, such as JPT1, show potential in modulating Aβ aggregation pathways.
• JPT1's ability to alter Aβ aggregation kinetics suggests a possible therapeutic avenue for Alzheimer's disease.
• Further research into peptoids could lead to novel strategies for preventing Aβ plaque formation.